85.51 -0.38 (-0.44%)
After hours: 4:20PM EDT
|Bid||85.89 x 900|
|Ask||86.27 x 1300|
|Day's Range||84.42 - 86.14|
|52 Week Range||45.88 - 86.50|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||36.42|
|Earnings Date||Nov 1, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.80|
Looking at Medpace Holdings, Inc.'s (NASDAQ:MEDP) earnings update in June 2019, analysts seem cautiously bearish, with...
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Teladoc's (TDOC) vast business presence in the growing telehealth industry with many deal wins and international expansion should drive long-term growth.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
The Zacks Analyst Blog Highlights: Industrial Logistics, Medpace, Unitil, DaVita and Telephone and Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals ...
Medpace stock leaped more than 15% this morning, following the Madisonville-based firm’s reported second quarter earnings on Monday afternoon. Medpace's stock closed Tuesday at $79.91, up $11.9 for the day, or nearly 18%. Medpace, which conducts clinical trials for companies worldwide that want to bring new drugs and medical devices to market (Nasdaq: MEDP), reported revenue of $214.1 million for the quarter that ended in June.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc ...
Medpace (MEDP) delivered earnings and revenue surprises of 28.57% and 6.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech stocks moved mostly sideways during the week, although there was a flurry of activity in the space. Earnings from the sector began to trickle in, with Bristol-Myers Squibb Co (NYSE: BMY ) reporting ...
Medpace (MEDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ensign Group (ENSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
A stock that more than quadrupled in the first half of 2019 shot a Cincinnati investment adviser to an enormous lead at the halfway point of the Courier’s annual stock-picking contest.
The Business Courier analyzed Greater Cincinnati's 25 locally based public companies to see which CEOs gave their shareholders the best value for the money.